Novartis Ag

Abbvie Inc.

Abb Vie Deutschland Gmbh & Co. Kg

Knoll Aktiengesellschaft

Martin Kaul

Stefan De Buck

Alessandra Vitaliti Garami

Maciej Cabanski

Bruno Bieth

Bruno Cenni

Arvind Kinhikar

Andrijana Radivojevic

Souvik Bhattacharya

Elliot Keith Chartash

Walid M Awni

Joachim Kempeni

Susan K Paulson

Lothar Daum

William T Barchuk

Joaquin Mario Valdes

Martin M Okun

William G Glass

Kenneth B Gordon

Sibylle Schaefer

Yanjun Bao

Christa Raab

Roswitha Stenzel

Yihua Gu

Tom C Harris

Julian Storim

Parvez M Mulani

Thomas Severin

Peter Noertersheuser

The present disclosure relates to methods for treating Chronic Spontaneous Urticaria using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Chronic Spontaneous Urticaria patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor

The present disclosure relates to methods for treating Sjögren's Syndrome disease using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Sjögren's Syndrome patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

Methods of treating Sjögren's syndrome using a Bruton's tyrosine kinase inhibitor

The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.

Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23

The invention relates to the use of TNF antagonists for producing drugs for the treatment of disorders characterized by elevated serum levels of interleukin-6.

Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6

Growing community of inventors

Neustadt, Germany

Martin Kaul